Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action
- PMID: 17848867
- DOI: 10.1097/NRL.0b013e3180f60bd8
Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action
Abstract
Background: Dextromethorphan (DM) is a widely-used antitussive. DM's complex central nervous system (CNS) pharmacology became of interest when it was discovered to be neuroprotective due to its low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism.
Review summary: Mounting preclinical evidence has proven that DM has important neuroprotective properties in various CNS injury models, including focal and global ischemia, seizure, and traumatic brain injury paradigms. Many of these protective actions seem functionally related to its inhibitory effects on glutamate-induced neurotoxicity via NMDA receptor antagonist, sigma-1 receptor agonist, and voltage-gated calcium channel antagonist actions. DM's protection of dopamine neurons in parkinsonian models may be due to inhibition of neurodegenerative inflammatory responses. Clinical findings are limited, with preliminary evidence indicating that DM protects against neuronal damage. Negative findings seem to relate to attainment of inadequate DM brain concentrations. Small studies have shown some promise for treatment of perioperative brain injury, amyotrophic lateral sclerosis, and symptoms of methotrexate neurotoxicity. DM safety/tolerability trials in stroke, neurosurgery, and amyotrophic lateral sclerosis patients demonstrated a favorable safety profile. DM's limited clinical benefit is proposed to be associated with its rapid metabolism to dextrorphan, which restricts its central bioavailability and therapeutic utility. Systemic concentrations of DM can be increased via coadministration of low-dose quinidine (Q), which reversibly inhibits its first-pass elimination. Potential drug interactions with DM/Q are discussed.
Conclusions: Given the compelling preclinical evidence for neuroprotective properties of DM, initial clinical neuroprotective findings, and clinical demonstrations that the DM/Q combination is well tolerated, this strategy may hold promise for the treatment of various acute and degenerative neurologic disorders.
Similar articles
-
An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.Med Hypotheses. 2012 Jun;78(6):693-702. doi: 10.1016/j.mehy.2012.02.012. Epub 2012 Mar 7. Med Hypotheses. 2012. PMID: 22401777
-
The chemical biology of clinically tolerated NMDA receptor antagonists.J Neurochem. 2006 Jun;97(6):1611-26. doi: 10.1111/j.1471-4159.2006.03991.x. J Neurochem. 2006. PMID: 16805772 Review.
-
Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist.J Pharmacol Exp Ther. 1999 Oct;291(1):399-408. J Pharmacol Exp Ther. 1999. PMID: 10490930
-
Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain.Eur J Neurosci. 2008 Feb;27(4):874-83. doi: 10.1111/j.1460-9568.2008.06062.x. Epub 2008 Feb 13. Eur J Neurosci. 2008. PMID: 18279363
-
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.Pharmacol Ther. 2016 Aug;164:170-82. doi: 10.1016/j.pharmthera.2016.04.010. Epub 2016 Apr 29. Pharmacol Ther. 2016. PMID: 27139517 Review.
Cited by
-
Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits.Clin Cancer Res. 2013 Aug 15;19(16):4446-54. doi: 10.1158/1078-0432.CCR-13-1179. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833301 Free PMC article.
-
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.Am J Neurodegener Dis. 2016 Mar 1;5(1):29-51. eCollection 2016. Am J Neurodegener Dis. 2016. PMID: 27073741 Free PMC article. Review.
-
Behavioral and Psychiatric Symptoms in Patients with Severe Traumatic Brain Injury: A Comprehensive Overview.Biomedicines. 2023 May 15;11(5):1449. doi: 10.3390/biomedicines11051449. Biomedicines. 2023. PMID: 37239120 Free PMC article. Review.
-
Dextromethorphan improves locomotor activity and decreases brain oxidative stress and inflammation in an animal model of acute liver failure.Clin Exp Hepatol. 2022 Sep;8(3):178-187. doi: 10.5114/ceh.2022.118299. Epub 2022 Aug 3. Clin Exp Hepatol. 2022. PMID: 36685267 Free PMC article.
-
Oral Dextromethorphan for the Treatment of Diabetic Macular Edema: Results From a Phase I/II Clinical Study.Transl Vis Sci Technol. 2018 Dec 17;7(6):24. doi: 10.1167/tvst.7.6.24. eCollection 2018 Nov. Transl Vis Sci Technol. 2018. PMID: 30584490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources